2010年
Increased Levels of Soluble LR11 in Cerebrospinal Fluid of Patients with Alzheimer Disease
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
- 巻
- 30
- 号
- 1
- 開始ページ
- 28
- 終了ページ
- 32
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1159/000315539
- 出版者・発行元
- KARGER
Background: Recent genetic and pathological studies have suggested that a lipoprotein receptor, LR11, is intricately implicated in the pathogenesis of Alzheimer disease (AD). We have recently established a novel sandwich ELISA, which enabled the sensitive quantification of a soluble LR11 (sLR11). By this ELISA, we attempted to determine the difference in the levels of CSF sLR11 in AD patients. Methods: We examined CSF from 29 AD patients, 20 frontotemporal lobar degeneration patients and 27 age-matched control subjects. The CSF sLR11 level as well as the levels of tau and beta-amyloid42 (A beta 42) were determined by sandwich ELISA. Results: The CSF tau level and tau/A beta 42 ratio were significantly increased (p < 0.01) in the AD patients. The CSF sLR11 level in the AD patients was significantly higher (p < 0.01) than that of the frontotemporal lobar degeneration patients and the controls. The APOE-epsilon 4-positive AD patients have higher sLR11 levels than the APOE-epsilon 4-negative patients (p < 0.01). Conclusions: These results suggest that the quantification of CSF sLR11 may serve as a biomarker of AD, although the diagnostic value for individual patients is limited. An elevated CSF sLR11 level in AD patients may be relevant to AD pathogenesis. Copyright (C) 2010 S. Karger AG, Basel
- リンク情報
- ID情報
-
- DOI : 10.1159/000315539
- ISSN : 1420-8008
- PubMed ID : 20689279
- Web of Science ID : WOS:000280936900005